However, the results of the multivariable Cox proportional hazards model (Table 4) showed that the 12-month increase in adiponectin was associated with a reduction in breast cancer risk (HR, 0.60; 95%CI, 0.36–1.00; Figure 2c). Here, ADIPOQ is linked to breast carcinoma.